AR032553A1 - Derivados de alfa-amino-n-hidroxi-acetamida. - Google Patents

Derivados de alfa-amino-n-hidroxi-acetamida.

Info

Publication number
AR032553A1
AR032553A1 ARP020100398A ARP020100398A AR032553A1 AR 032553 A1 AR032553 A1 AR 032553A1 AR P020100398 A ARP020100398 A AR P020100398A AR P020100398 A ARP020100398 A AR P020100398A AR 032553 A1 AR032553 A1 AR 032553A1
Authority
AR
Argentina
Prior art keywords
derivatives
amino
triazol
acetamide
hydroxi
Prior art date
Application number
ARP020100398A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR032553A1 publication Critical patent/AR032553A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente se refiere a derivados de alfa-amino-N-hidroxi-acetamida de la formula (1), en donde: R es dialquilamino inferior-amino, 1,2,3-triazol-1-ilo, 1,2,3-triazol-2-ilo, o 1,2,4-triazol-4-ilo, m representa un entero de hasta e incluyendo 10, y n representa un entero de 0 hasta e incluyendo 10, o una sal de los mismos; a procesos para su preparacion, a composiciones farmacéuticas que comprenden estos derivados del ácido hidroxámico, al uso de estos derivados del ácido hidroxámico como medicamentos y a un método para el tratamiento de condiciones o enfermedades mediadas por las metaloproteinasas degradantes de matriz (MMP) utilizando estos derivados solos o en combinacion con uno o más agentes terapéuticos diferentes.
ARP020100398A 2001-02-09 2002-02-07 Derivados de alfa-amino-n-hidroxi-acetamida. AR032553A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0103303.4A GB0103303D0 (en) 2001-02-09 2001-02-09 Organic compounds

Publications (1)

Publication Number Publication Date
AR032553A1 true AR032553A1 (es) 2003-11-12

Family

ID=9908475

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100398A AR032553A1 (es) 2001-02-09 2002-02-07 Derivados de alfa-amino-n-hidroxi-acetamida.

Country Status (10)

Country Link
US (3) US7112611B2 (es)
EP (1) EP1360175A1 (es)
JP (1) JP4262982B2 (es)
CN (1) CN100509773C (es)
AR (1) AR032553A1 (es)
AU (1) AU2002249197A1 (es)
CA (1) CA2435611C (es)
GB (1) GB0103303D0 (es)
PE (1) PE20020845A1 (es)
WO (1) WO2002064552A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
BRPI0709677A2 (pt) * 2006-03-29 2011-07-19 Novartis Ag inibidores seletivos das mmp à base de hidroxamato
US20100234378A1 (en) * 2006-08-22 2010-09-16 Array Biopharma Inc. Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
EP2934555B1 (en) 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
US20180353175A1 (en) * 2017-06-13 2018-12-13 Ethicon Llc Surgical Fastener with Broad Spectrum MMP Inhibitors
US11058804B2 (en) 2017-06-13 2021-07-13 Ethicon Llc Surgical fastener device for the prevention of ECM degradation
CN110769866B (zh) * 2017-06-13 2022-07-29 爱惜康有限责任公司 具有可控愈合的外科缝合器
US10939911B2 (en) 2017-06-13 2021-03-09 Ethicon Llc Surgical stapler with end effector coating
CN110740764B (zh) * 2017-06-13 2022-05-27 爱惜康有限责任公司 具有广谱mmp抑制剂的外科紧固件

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2513826A (en) * 1946-12-05 1950-07-04 Gen Aniline & Film Corp Aromatic sulfonhydrazides
US4772733A (en) 1986-07-17 1988-09-20 Hercules Incorporated Epoxy-azides
US4806528A (en) * 1987-09-04 1989-02-21 Hanreich Reinhard G Process for the preparation of 2-(2-chloroethoxy)-benzenesulfonamide
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2682498A1 (fr) * 1991-10-15 1993-04-16 Kodak Pathe Colorants comprenant des macrocycles thioethers.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9503749D0 (en) * 1995-02-24 1995-04-12 British Biotech Pharm Synthesis of hydroxamic acid derivatives
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
NZ325939A (en) 1996-01-23 2000-06-23 Shionogi & Co Sulphonated amino acid derivatives and matrix metalloproteinase inhibitors (MMP) containing these derivatives
WO1997044315A1 (en) 1996-05-17 1997-11-27 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
WO1997045402A1 (fr) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Derives de phenylsulfonamide
WO1998018754A1 (en) 1996-10-28 1998-05-07 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
IL128545A0 (en) 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
ID22799A (id) 1997-02-03 1999-12-09 Pfizer Prod Inc Turunan-turunan asam arilsulfonilamino hidroksamat
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
ES2165640T3 (es) 1997-05-09 2002-03-16 Hoechst Ag Acidos diaminocarboxilicos sustituidos.
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
IL127496A0 (en) 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
NZ505968A (en) 1998-02-04 2003-03-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
JPH11236369A (ja) 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk スルホンアミド誘導体及びその製造法並びにこれを含有する医薬組成物
PA8469301A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimientos para la preparacion de acidos hidroxamicos.
RU2232751C2 (ru) 1998-12-22 2004-07-20 Ф.Хоффманн-Ля Рош Аг Производные сульфонамидов и фармацевтическая композиция
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AR035313A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2002064552A1 (en) 2002-08-22
GB0103303D0 (en) 2001-03-28
JP2004523545A (ja) 2004-08-05
US20040082630A1 (en) 2004-04-29
US7112611B2 (en) 2006-09-26
CN100509773C (zh) 2009-07-08
WO2002064552A8 (en) 2002-12-12
CA2435611C (en) 2011-07-12
EP1360175A1 (en) 2003-11-12
AU2002249197A1 (en) 2002-08-28
US7291634B2 (en) 2007-11-06
US20080176916A1 (en) 2008-07-24
JP4262982B2 (ja) 2009-05-13
US20060270719A1 (en) 2006-11-30
CN1525956A (zh) 2004-09-01
US7659293B2 (en) 2010-02-09
PE20020845A1 (es) 2002-10-30
CA2435611A1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
DK1361882T3 (da) 4-fluor-N-indan-2-ylbenzamid og dets anvendelse som farmaceutisk middel
PA8591701A1 (es) Derivados de pirrolopirimidina
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066312A (es) Derivados piridilo y su uso como agentes terapéuticos
SE0200979D0 (sv) New compounds
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
PE20030823A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
ATE381535T1 (de) Phenethanolaminderivate
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
NO20062905L (no) Nye hydroksaminsyreestere og farmasoytisk anvendelse derav
UY27169A1 (es) Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
BR9910849A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, tal como um humano, formulação farmacêutica, uso de um composto, processo para preparação do composto, e, derivado protegido.
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
AR032553A1 (es) Derivados de alfa-amino-n-hidroxi-acetamida.
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
SE0100569D0 (sv) New compounds
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
PE20040961A1 (es) Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel
BRPI0408689A (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación

Legal Events

Date Code Title Description
FB Suspension of granting procedure